Navigation Links
Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in patients suffering from systemic sclerosis, a systemic fibrotic disease, by early 2012.

"The Phase 1 clinical study in healthy volunteers demonstrated that AM152 is safe and well-tolerated at doses which are expected to provide a full range of receptor coverage in humans," said Isabelle DeArmond, Vice President, Clinical Development. "These results enable us to study AM152 at a wide range of doses in patients suffering from fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Initiating a Phase 2a study in patients suffering from systemic sclerosis will be an important milestone for the team at Amira; we look forward to better understanding the potential therapeutic benefit of AM152."

AM152 is a novel LPA1 receptor antagonist developed by the scientists at Amira.  Preclinical data has demonstrated that antagonism of the LPA1 receptor inhibits fibrosis in several disease models.  Much of these data has been previously presented and published by Amira scientists and colleagues.  Amira Pharmaceuticals also recently announced that AM152 was granted Orphan Drug Status by the FDA for patients suffering from idiopathic pulmonary fibrosis (IPF).

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Our team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.  For more information, visit www.amirapharm.com.

Media Contact
Ian Stone
Russo Partners
Tel: +1 619 528 2220
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
2. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
3. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
4. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
5. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
6. Visage Imaging Releases Amira 5.3
7. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
8. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
9. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016 Intouch Solutions, a leading marketing ... industry-wide trend regarding the evolution of digital sales ... efficiently deliver compelling sales presentations via tablets. After ... in 2015, Intouch uncovered that while most pharmaceutical ... DSAs, many are not using them effectively during ...
(Date:2/10/2016)... Feb. 9, 2016 On Tuesday, ... (FDA) met with its Arthritis Advisory Committee ... of Johnson & Johnson,s Remicade and most ... in the U.S. The Biologics Prescribers Collaborative ... - Alliance for Patient Access, American Association ...
(Date:2/10/2016)... , February 10, 2016 The campaign aims ... 5 years reach the milestone of their 5 th ... ensure 2,50,532 children between the ages of 2 - ...   --> The campaign aims to ... years reach the milestone of their 5 th birthday   ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on Wednesday ... , an emergency medicine professional association, to support the organization's newly established physician ... Academy of Emergency Medicine, or AAEM, seeks to empower emergency physicians to control ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Peyman Ghasri, skin doctor ... variety of comprehensive procedures for facial enhancement. The treatments now available at Castle ... and nasal reshaping. , As a result, patients can improve virtually every ...
(Date:2/10/2016)... ... February 10, 2016 , ... Gout is like no other ... that is often severe, with intense swelling and redness. It is triggered by the ... but older adults are the most susceptible, according to the February 2016 issue of ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , ... with Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... publication date is March 16, 2016. A free review copy is available to ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... 1 UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions ... Division - Time: 7:00pm – 10:00pm | Ticket Prices $30, Social Media: ...
Breaking Medicine News(10 mins):